Evidence map›Paper›PMID 40899852›Full record

ArticleJournal of bacteriology2025

A

Akanksha Varshney, John N Alumasa, Amber Miller, Kenneth C Keiler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bacteriology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Microbiology (Reading, England) · 2026
    Article
  4. bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

  • Update of
    A2025
5 · Who and what money

Authors and funding

4 authors.

Akanksha VarshneyDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA.ORCID 0009-0007-4524-3523
John N AlumasaDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania, USA.
Amber MillerDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania, USA.
Kenneth C KeilerDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA.ORCID 0000-0001-8753-335X

Funding

Physiology of ribosome rescue in bacteriaR01GM121650 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI KEILER, KENNETH C · 2017 to 2025
$3.8M
Targeting trans-translation to kill M. tuberculosis non-replicating persister cellsR01AI158706 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI ANTHONY D BAUGHN, Kenneth C Keiler · 2022 to 2026
$3.4M
National Institute of Allergy and Infectious Diseases AI158706NIAID NIH HHS R01 AI158706NIGMS NIH HHS GM121650NIGMS NIH HHS R01 GM121650
6 · The paper itself

Abstract

New antibiotics with novel mechanisms of action are needed to treat infections by multidrug-resistant strains of

Indexed as

Antitubercular AgentsBacterial ProteinsMycobacterium tuberculosisProtein BiosynthesisRibosomal ProteinsTriazolesMicrobial Sensitivity TestsProtein BindingRibosomesAntitubercular AgentsBacterial ProteinsRibosomal ProteinsTriazolesbL12Mycobacterium tuberculosisribosometmRNAtrans-translation

Identifiers

PMID40899852
PMCPMC12548414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.